Christopher Rigell1, Guihua Zhai1, Kyle Lee1,
Sharon Samuel1, Amber Martin1, Timothy Beasley1,
Long Shan Li2, David Boothman2, Kurt Zinn1
of Alabama at Birmingham, Birmingham, AL, United States; 2Radiation
Oncology, UT Southwestern Medical Center, Dallas, TX, United States
Anti-EMMPRIN monotherapy has demonstrated strong anti-tumor effect via preventing tumor-cell invasion and neovascularization. However, care must be taken when applying anti-EMMPRIN antibody in combination with another small-molecule chemotherapeutic agent like gemcitabine, because the antiangiogenic effect of anti-EMMPRIN antibody may excessively decrease the tumor vasculature for hypovascular tumors, reducing the tumor delivery of the chemotherapeutic agent while increasing tumor hypoxia. In this study, differential therapeutic efficacy of anti-EMMPRIN antibody combined with non-targeting small-molecule chemotherapy drugs was confirmed according to tumor vascularity, and a clinical protocol to enable personalized treatment of pancreatic cancer patients based on DCE-MRI was suggested.